Catalyst Biosciences (NASDAQ: CBIO) and Onconova Therapeutics (NASDAQ:ONTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, institutional ownership, dividends and analyst recommendations.
Insider and Institutional Ownership
5.6% of Catalyst Biosciences shares are held by institutional investors. Comparatively, 15.5% of Onconova Therapeutics shares are held by institutional investors. 5.0% of Catalyst Biosciences shares are held by company insiders. Comparatively, 27.3% of Onconova Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Catalyst Biosciences and Onconova Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Catalyst Biosciences||$561,999.00||25.85||-$19.79 million||($17.78)||-0.19|
|Onconova Therapeutics||$4.28 million||4.26||-$19.88 million||($4.02)||-0.48|
Catalyst Biosciences has higher revenue, but lower earnings than Onconova Therapeutics. Onconova Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Biosciences, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings for Catalyst Biosciences and Onconova Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Catalyst Biosciences currently has a consensus price target of $24.50, indicating a potential upside of 618.48%. Onconova Therapeutics has a consensus price target of $8.00, indicating a potential upside of 316.67%. Given Catalyst Biosciences’ higher probable upside, research analysts plainly believe Catalyst Biosciences is more favorable than Onconova Therapeutics.
This table compares Catalyst Biosciences and Onconova Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Catalyst Biosciences has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, Onconova Therapeutics has a beta of 0.06, meaning that its share price is 94% less volatile than the S&P 500.
Catalyst Biosciences beats Onconova Therapeutics on 7 of the 11 factors compared between the two stocks.
About Catalyst Biosciences
Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.
About Onconova Therapeutics
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company’s lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.
What are top analysts saying about Catalyst Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Catalyst Biosciences Inc. and related companies.